不同时机应用EPO治疗早产儿贫血的效果及对血常规指标的影响

doi:10.3969/j.issn.1671-7171.2023.05.010

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1137 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the effect of using erythropoietin (EPO) at different time points in the treatment of anemia in premature infants and its impact on blood routine indicators. 【Methods】A total of 90 premature infants with anemia admitted to two hospitals from July 2020 to July 2022 were selected and divided into an observation group and a control group based on different treatment times,with 45 cases in each group. The observation group received EPO treatment after the second week of birth,while the control group received EPO treatment after the third week of birth. Both groups were treated until the fifth week of birth. The levels of anemia indexes [hemoglobin (Hb),hematocrit (HCT),reticulocyte count (Ret)] in the two groups were measured before and after treatment. The levels of blood routine indicators (RBC,MCHC and BPC) were measured before and after treatment in both groups. Before and after treatment,the levels of hematopoietic substances [folic acid,vitamin B₁₂ and ferritin (SF)] in two groups were tested,and the number of blood transfusions during the treatment period was recorded and compared. The blood transfusion rate was calculated,and the occurrence of adverse reactions in the two groups was observed and compared.【Results】After treatment,there was no significant change in Hb and HCT levels in the observation group compared to before treatment (P>0.05),while Ret levels in the observation group were higher than before treatment (P<0.05). The Hb,HCT,Ret levels in the control group were lower than before treatment (P<0.05),and the Hb,HCT,Ret levels in the observation group were higher than those in the control group (P<0.05). After treatment,there was no significant change in the RBC level in the observation group compared to before treatment (P>0.05). The MCHC level in the observation group and the RBC and MCHC levels in the control group decreased significantly compared to before treatment. The BPC level in the observation group and the control group increased significantly compared to before treatment (P<0.05),and the RBC level in the observation group was significantly higher than that in the control group (P<0.05). There was no statistically significant difference in the levels of MCHC and BPC between the observation group and the control group (P>0.05). After treatment,the levels of folic acid,vitamin B₁₂,and SF in the observation group and the levels of folic acid and vitamin B₁₂ in the control group showed no statistically significant difference compared to before treatment (P>0.05). The SF levels in the control group were lower than before treatment (P<0.05),and the SF levels in the observation group were higher than those in the control group (P<0.05). There was no statistically significant difference in blood transfusion rates between the two groups (P=0.398). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). 【 Conclusion 】 Applying EPO to treat anemia in premature infants at the second week of birth may not significantly reduce the transfusion rate,but it can effectively improve the anemia status of the children and has high safety.

Key words： Infant, Premature Anemia, Neonatal/DT Erythropoietin/TU

Received: 08 August 2022

PACS:

R722

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2023.05.010 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2023/V40/I5/676

[1] DANIELLE C. AGA clinical practice guidelines on the gastrointestinal evaluation of iron deficiency anemia[J].Gastroenterology,2020,159(3):1085-1094.
[2] CIBULSKIS C C,MAHESHWARI A,RAO R,et al. Anemia of prematurity:How low is too low?[J].J Perinatol,2021,41(6):1244-1257.
[3] 王思璐,谢晓恬.促红细胞生成素治疗早产儿贫血研究进展[J].中华实用儿科临床杂志,2019,34(23):1831-1833.
[4] 杨晓晶.不同剂量的重组人促红细胞生成素治疗早产儿贫血的有效性及安全性研究[J].特别健康,2021,(36):73-74.
[5] VISWANATHAN S,JADCHERLA S. Anemia of prematurity and oral feeding milestones in premature infants[J].Am J Perinatol,2021,38(6):553-559.
[6] 冯晋楠,王又平,朱梦茹,等.不同胎龄及不同性别早产儿出生后24 h内桡动脉血红细胞参数参考范围[J].中华检验医学杂志,2021,44(3):222-227.
[7] 郝素芳,崔红.早产儿贫血发病的相关因素分析[J].中国妇幼保健,2016,31(7):1454-1456.
[8] TSIFTSOGLOU A S. Erythropoietin (EPO) as a key regulator of erythropoiesis,bone remodeling and endothelial transdifferentiation of multipotent mesenchymal stem cells (MSCs):Implications in regenerative medicine[J].Cells,2021,10(8):2140.
[9] MCALLISTER J,LI Z,LIU J,et al. Erythropoietin dose optimization for anemia in chronic kidney disease using recursive zone model predictive control[J].IEEE Trans Control Sys Technol,2019,27(3):1181-1193.
[10] 赵兴丹,符小玲,翁艾罕.极低出生体重儿贫血相关因素及评估模型建立[J].临床输血与检验,2022,24(2):202-206.
[11] 何兴宇,边朋,张怡.促红细胞生成素在早产儿贫血中的治疗时机及对不同胎龄早产儿贫血的疗效[J].中国妇幼保健,2019,34(14):3230-3232.
[12] 李伟英,陈崴.肾性贫血铁代谢指标的评估、判读及应用[J].中国实用内科杂志,2020,40(12):1010-1014.
[13] 张春梅,朱春,童梅玲,等.小剂量补铁预防早产儿贫血的疗效分析[J].中国儿童保健杂志,2018,26(6):683-684.